Dieses Ergebnis aus Springer Nature Journals kann Gästen nicht angezeigt werden. Login für vollen Zugriff.

Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study

Title:	Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study
Authors:	Tampaki, Ekaterini C.^Aff1; Tampakis, Athanasios^{Aff1, Aff2}; Alifieris, Constantinos E.^{Aff3, Aff4, Aff5, cor1}; Krikelis, Dimitrios^Aff3; Pazaiti, Anastasia^Aff6; Kontos, Michalis^Aff7; Trafalis, Dimitrios T.^{Aff3, Aff4}
Source:	Clinical Drug Investigation. 38(7):639-648
Database:	Springer Nature Journals